AlphAIalphai — Financial news for AI agents
investing.comAUG 73 min read$DVA

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

Original reporting
investing.com
Published Aug 7, 2026, 9:54 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMarket movers
Primary signal
$DVA
Bullish
medium confidence
Mentioned
$DVA
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$DVABullishMed
01

Why it matters

The article attributes today’s +2.1% pre-open move to TD Cowen’s upgrade and higher price target, framing the post-earnings dip as a buying opportunity while pointing to MOTheR trial results as supportive for patient volume without major equipment spend.

02

Market read

A same-day analyst upgrade with a specific PT change is presented as the immediate driver of DaVita’s early strength, against a backdrop of risk-on markets.

03

What to watch

Legal proceedings and potential Berkshire Hathaway share sales are flagged as long-term risks, which can limit multiple expansion even on upgrades.

Relevance 7/10Novelty 5/10Timing: pre-market today

Background

DaVita’s Q2 2026 results beat consensus on EPS and revenue, but the stock sold off on flat full-year guidance and a modest decline in revenue per treatment.

Company-level read

Ticker impact

$DVABullishMedium confidence
Context

TD Cowen upgraded DaVita from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial read-through.

Expected impact

Support for continued pre-market strength, but follow-through may be capped if investors refocus on flat guidance and margin headwinds.

Evidence & confidence

The only fresh, company-specific catalyst in the text is the analyst upgrade with a higher PT; the rest is recap of Q2 results and previously cited risks.

Market effects

Sector

Reinforces bullish sentiment toward kidney dialysis/healthcare services names via incremental analyst conviction.

Regional

None specified beyond broad US index strength.

Global

None specified.

Counterpoint

What could challenge this read

The upgrade may fade if the market continues to discount DaVita’s flat full-year guidance and revenue per treatment softness despite the PT increase.

Key entities

  • company
    DaVita HealthCare Partners Inc

    Kidney dialysis provider whose shares rose ~2% pre-open after a TD Cowen upgrade and higher price target.

  • analyst_firm
    TD Cowen

    Upgraded DaVita from Hold to Buy and lifted its price target to $220 from $201.

  • clinical_trial
    MOTheR trial

    Trial results cited as enabling a new care modality expected to support patient volume growth.

  • institution
    Berkshire Hathaway

    Flagged as a potential source of share sales risk in the long term.

Read at source← All news

Related articles

AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min
AUG 5
$DVAMed

DaVita Q2 Earnings Call Highlights

DaVita (NYSE:DVA) reported Q2 earnings call highlights. Revenue per treatment fell about $2 sequentially, while patient care costs per treatment dropped about $3. Full-year guidance remains 1% to 2% revenue-per-treatment growth and adjusted operating income midpoint of $2.2B, EPS $14.65. CMS proposed adding phosphate binders to 2027 dialysis bundles; DaVita plans expanded HD deployment.

yahoo.com7 min
AUG 4
$DVAMedAI 8/10

DaVita HealthCare: Q2 Earnings Snapshot

DaVita HealthCare Partners Inc. (DVA) reported Q2 net income of $265.4 million and profit of $4.02 per share. Revenue was $3.55 billion. The company forecast full-year earnings of $14.10 to $15.20 per share, according to the AP earnings snapshot.

durangoherald.com2 min
AUG 4
$DVAMedAI 8/10

DaVita Inc. 2nd Quarter 2026 Results

DaVita Inc. (NYSE: DVA) reported Q2 2026 results for the quarter ended June 30, 2026. Consolidated revenues were $3.554 billion, operating income $579 million, and diluted EPS $4.02. Operating cash flow was $490 million and free cash flow $256 million. The company added a $500 million Term Loan B-2 tranche and repurchased 2.2 million shares at $154.95 average.

prnewswire.com6 min